Phase 2Active, not recruiting
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
- Sponsor
- BPGbio (Industry)
- Enrolment
- 50 planned
- Conditions
- Glioblastoma; Glioblastoma Multiforme
- Interventions
- BPM31510; Vitamin K1; Temozolomide (TMZ); Radiation
- Ages
- adults, older adults
- Registry
- NCT04752813
From the registry
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Primary outcomes
- Efficacy will be assessed by subject progression free survival